BC43.20 Nonfamilial restrictive cardiomyopathy International Classification of Diseases for Mortality and Morbidity Statistics, 11th Revision, v2024-01 Nonfamilial restrictive cardiomyopathy is restrictive cardiomyopathy secondary to an acquired systemic disorder that is known to be associated with restrictive cardiomyopathy such as amyloidosis, scleroderma, sarcoidosis, or anthracycline therapy.
postcoordination Add Stem and/or Extension codes to form a cluster code which adds detail to the condition.
Associated with - multiple selections are allowed [select] 4B20 Sarcoidosis – 4B20.0 Sarcoidosis of lung – 4B20.1 Sarcoidosis of lymph nodes – 4B20.2 Sarcoidosis of the digestive system – 4B20.3 Neurosarcoidosis – 4B20.4 Ocular sarcoidosis – 4B20.5 Cutaneous sarcoidosis – 4B20.Y Other specified sarcoidosis – 4B20.Z Sarcoidosis, unspecified – 5D01 Tumour lysis syndrome –– EE7Y Other specified disorders of cutaneous connective tissue –– PB20 Unintentional exposure to or harmful effects of opioids or related analgesics –– PB21 Unintentional exposure to or harmful effects of sedative hypnotic drugs or other CNS depressants –– PB22 Unintentional exposure to or harmful effects of psychostimulants –– PB23 Unintentional exposure to or harmful effects of cannabinoids or hallucinogens –– PB24 Unintentional exposure to or harmful effects of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs –– PB25 Unintentional exposure to or harmful effects of antidepressants –– PB26 Unintentional exposure to or harmful effects of antipsychotics –– PB27 Unintentional exposure to or harmful effects of antiepileptics or antiparkinsonism drugs –– PB28 Unintentional exposure to or harmful effects of other or unspecified drug, medicament or biological substance –– PB29 Unintentional exposure to or harmful effects of multiple drugs, medicaments or biological substances –– PH40 Exposure to or harmful effects of undetermined intent of opioids or related analgesics –– PH41 Exposure to or harmful effects of undetermined intent of sedative hypnotic drugs or other CNS depressants –– PH42 Exposure to or harmful effects of undetermined intent of psychostimulants –– PH43 Exposure to or harmful effects of undetermined intent of cannabinoids or hallucinogens –– PH44 Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs –– PH45 Exposure to or harmful effects of undetermined intent of antidepressants –– PH46 Exposure to or harmful effects of undetermined intent of antipsychotics –– PH47 Exposure to or harmful effects of undetermined intent of antiepileptics or antiparkinsonism drugs ––– PH47.0 Harmful effects of or exposure to mixed antiepileptics, not elsewhere classified, undetermined intent ––– PH47.Z Undetermined intent: Harmful effects of and exposure to noxious substances: Drugs, medicaments or biological substances: Unspecified antiepileptics or antiparkinsonism drugs –– PH48 Exposure to or harmful effects of undetermined intent of other or unspecified drugs, medicaments or biological substances –– PH49 Exposure to or harmful effects of undetermined intent of multiple drugs, medicaments or biological substances – PL00 Drugs, medicaments or biological substances associated with injury or harm in therapeutic use – PL01 Complementary or traditional medicines associated with injury or harm in therapeutic use –– PL01.0 Complementary or traditional medicines associated with injury or harm in therapeutic use, Herbal Preparations or Formulas –– PL01.1 Complementary or traditional medicines associated with injury or harm in therapeutic use, Dietary Supplements, Vitamins or Minerals –– PL01.2 Complementary or traditional medicines associated with injury or harm in therapeutic use, Complementary or Traditional Medicines, not elsewhere classified –– PL01.Y Other specified complementary or traditional medicines associated with injury or harm in therapeutic use –– PL01.Z Complementary or traditional medicines associated with injury or harm in therapeutic use, unspecified – PL0Z Substances associated with injury or harm in therapeutic use, unspecified PL13 Mode of injury or harm associated with exposure to a drug, medicament or biological substance – PL13.0 Overdose of substance, as mode of injury or harm – PL13.1 Underdosing, as mode of injury or harm – PL13.2 Drug-related injury or harm in the context of correct administration or dosage, as mode of injury or harm – PL13.3 Incorrect substance, as mode of injury or harm – PL13.5 Incorrect administration of drug or medicament, as mode of injury – PL13.6 Medication or substance that is known to be an allergen, as mode of injury or harm – PL13.7 Medication or substance that is known to be contraindicated for the patient, as mode of injury or harm – PL13.8 Expired or deteriorated medication or substance, as mode of injury or harm – PL13.9 Drug or substance interactions, as mode of injury or harm – PL13.A Inappropriate stoppage or discontinuation of drug, as mode of injury or harm – PL13.Y Other specified mode of injury or harm associated with exposure to a drug, medicament or biological substance – PL13.Z Mode of injury or harm associated with exposure to a drug, medicament or biological substance, unspecified –– PL13.50 Incorrect route of drug or medicament, as mode of injury –– PL13.51 Incorrect rate of drug or medicament, as mode of injury –– PL13.52 Incorrect timing of drug or medicament, as mode of injury –– PL13.53 Incorrect duration of drug or medicament, as mode of injury –– PL13.5Y Other specified incorrect administration of drug or medicament, as mode of injury –– PL13.5Z Incorrect administration of drug or medicament, as mode of injury, unspecified
synonyms Nonfamilial restrictive cardiomyopathy Secondary restrictive cardiomyopathy Restrictive cardiomyopathy due to endomyocardial abnormality Endomyocardial cardiomyopathy Endomyocardial disease Endomyocardial sclerosis Endomyocardial fibrosis endomyofibrosis (deprecated) Tropical endomyocardial fibrosis TEMF - [tropical endomyocardial fibrosis] EMF - [endomyocardial fibrosis] Davies disease African endomyocardial fibrosis Hypereosinophilic syndrome constrictive endocarditis (deprecated) Loeffler endocarditis Löffler parietal fibroplastic endocarditis Endocarditis fibroplastica with eosinophilia Endocarditis parietalis fibroplastica Fibroplastic parietal endocarditis Myocarditis secondary to idiopathic hypereosinophilic syndrome Primary eosinophilic Endomyocardial restrictive cardiomyopathy Lymphocytic hypereosinophilic syndrome Myeloproliferative hypereosinophilic syndrome Restrictive cardiomyopathy due to radiation toxicity Restrictive cardiomyopathy due to carcinoid syndrome Restrictive cardiomyopathy due to scleroderma Restrictive cardiomyopathy due to sarcoidosis Restrictive cardiomyopathy due to drugs Restrictive cardiomyopathy due to anthracycline toxicity Wild type transthyretin-related amyloid cardiomyopathy senile systemic amyloidosis SSA - [senile systemic amyloidosis} WTTA - [wild-type transthyretin amyloidosis Wild type ATTR - [transthyretin] amyloidosis
Thank you for choosing Find-A-Code, please Sign In to remove ads.
Quick, Current, Complete - www.findacode.com